Théodore VinaisBrigitte PlansontAlexis ParentéPhilippe NubukpoAurélie LacroixNakhchivan State University2026-06-042026-06-042026-05-08https://doi.org/10.1016/j.genhosppsych.2026.05.007https://rims.khazar.org/handle/123456789/1228Purpose: Psychiatric disorders, including recurrent unipolar depression and bipolar disorder, are associated with increased cancer risk and premature mortality. Alcohol use disorder (AUD) and immune dysregulation may underlie these associations. Objectives: This exploratory study investigated whether inflammatory and neuroplasticity-related biomarkers differ according to cancer history and alcohol abstinence in patients with AUD and depressive disorders. Methods: We conducted a retrospective analysis of 172 patients from a French clinical cohort, including 53 participants with longitudinal inflammatory and neuroplasticity biomarkers assessed over six months. Results: Among the study sample (mean age: 45.7 years; 134 men/38 women), 12.8% had cancer history, predominantly ear, nose and throat (27.3%) and breast cancers (22.7%), with psychiatric diagnoses preceding cancer onset by approximately 15 years. IL-8 (Interleukin-8) levels were significantly higher in participants with cancer history and depressive disorders, independently of alcohol abstinence, suggesting a stable cancerassociated inflammatory signature. In contrast, TNF-α (Tumor Necrosis Factor-alpha) levels varied according to alcohol abstinence status over time, distinguishing abstinent from non-abstinent individuals independently of cancer history. BDNF (Brain-Derived Neurotrophic Factor) levels did not differ according to cancer history or abstinence. Conclusions: These findings suggest that distinct inflammatory pathways may characterize cancer history and alcohol abstinence in patients with AUD and depressive disorders. IL-8 and TNF-α may represent candidate biomarkers associated with cancer-associated inflammation and alcohol abstinence status, respectively. Given the small cancer subgroup, these results should be interpreted as exploratory and hypothesis-generating. Future studies integrating genetic, epigenetic, and molecular markers are needed to refine these associations and support personalized approaches.Inflammation AUD Depression Cancer Biomarkersjournal-article